Department of Biochemistry, Genetic Engineering and Biotechnology Research Division, National Research Centre , Giza , Egypt.
High Throughput Molecular and Genetic Laboratory, Center for Excellences for Advanced Sciences, National Research Centre , Giza , Egypt.
Arch Physiol Biochem. 2019 Dec;125(5):456-464. doi: 10.1080/13813455.2018.1482355. Epub 2018 Jun 20.
Aberrant expression of miRNAs has a link with tumorgenesis and their deregulation is reported in biological fluids of cancer patients. Authors aimed to investigate the diagnostic role of miRNA-17-5p, miR-155 and miRNA-222 in serum samples from breast cancer patients ( = 80), benign breast patients ( = 40) and healthy individuals ( = 30) using quantitative real-time PCR technique. Median levels of investigated markers revealed significant increase in primary breast cancer followed by benign and control groups. Investigated miRNAs reported significant relation with clinical stages and histological grading, while only miRNA-17-5p showed significant relation with hormone receptors. When considering investigated miRNAs as compared to tumor marker, their sensitivities were superior over tumor markers for early diagnosis of breast cancer, detection of early stages and low grades breast cancer patients. In conclusion, detection of the miRNA-17-5p, miR-155 and miRNA-222 expression levels in serum samples is significant promising molecular markers for early breast cancer diagnosis.
miRNA 的异常表达与肿瘤发生有关，其在癌症患者的生物体液中失调已有报道。作者旨在通过定量实时 PCR 技术研究血清样本中 miRNA-17-5p、miR-155 和 miRNA-222 在乳腺癌患者（n=80）、良性乳腺患者（n=40）和健康个体（n=30）中的诊断作用。研究标志物的中位数水平显示原发性乳腺癌显著增加，其次是良性和对照组。研究表明，这些 miRNA 与临床分期和组织学分级有显著关系，而只有 miRNA-17-5p 与激素受体有显著关系。当将研究中的 miRNA 与肿瘤标志物进行比较时，它们的敏感性优于肿瘤标志物，可用于早期诊断乳腺癌、检测早期和低级别乳腺癌患者。总之，检测血清样本中 miRNA-17-5p、miR-155 和 miRNA-222 的表达水平是早期乳腺癌诊断有前途的分子标志物。
